Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
Fractyl Health (NASDAQ:GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has scheduled two important investor events. The company will release its Q2 2025 financial results and provide business updates on August 12, 2025, at 4:30 p.m. ET.
Additionally, CEO Harith Rajagopalan will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 11:30 a.m. ET. Both events will be accessible via webcast through the company's investor relations website.
Fractyl Health (NASDAQ:GUTS), un'azienda specializzata in terapie metaboliche per il trattamento dell'obesit脿 e del diabete di tipo 2, ha programmato due eventi importanti per gli investitori. La societ脿 pubblicher脿 i suoi risultati finanziari del secondo trimestre 2025 e fornir脿 aggiornamenti aziendali il 12 agosto 2025 alle 16:30 ET.
Inoltre, l'amministratore delegato Harith Rajagopalan parteciper脿 alla 45陋 Conferenza Annuale sulla Crescita di Canaccord Genuity il 13 agosto 2025 alle 11:30 ET. Entrambi gli eventi saranno disponibili in webcast tramite il sito web delle relazioni con gli investitori della societ脿.
Fractyl Health (NASDAQ:GUTS), una empresa terap茅utica metab贸lica especializada en tratamientos para la obesidad y la diabetes tipo 2, ha programado dos eventos importantes para inversores. La compa帽铆a publicar谩 sus resultados financieros del segundo trimestre de 2025 y ofrecer谩 actualizaciones comerciales el 12 de agosto de 2025 a las 4:30 p.m. ET.
Adem谩s, el CEO Harith Rajagopalan presentar谩 en la 45陋 Conferencia Anual de Crecimiento de Canaccord Genuity el 13 de agosto de 2025 a las 11:30 a.m. ET. Ambos eventos estar谩n disponibles v铆a webcast a trav茅s del sitio web de relaciones con inversores de la compa帽铆a.
Fractyl Health (NASDAQ:GUTS)電� 牍勲 氚� 鞝�2順� 雼闺嚚氤� 旃橂毳� 鞝勲鞙茧 頃橂姅 雽�靷� 旃橂 須岇偓搿�, 霊� 臧�歆� 欷戩殧頃� 韴瀽鞛� 頄夓偓毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橁碃 2025雲� 8鞗� 12鞚� 鞓ろ泟 4鞁� 30攵�(霃欕秬鞁滉皠)鞐� 靷梾 順勴櫓鞚� 鞐呺嵃鞚错姼頃� 鞓堨爼鞛呺媹雼�.
霕愴暅, CEO 頃橂Μ鞀� 霛检瀽臧�韺旊瀫(Harith Rajagopalan)鞚� Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐愳劀 2025雲� 8鞗� 13鞚� 鞓れ爠 11鞁� 30攵�(霃欕秬鞁滉皠)鞐� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 霊� 頄夓偓 氇憪 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Fractyl Health (NASDAQ:GUTS), une entreprise sp茅cialis茅e dans les th茅rapies m茅taboliques pour le traitement de l'ob茅sit茅 et du diab猫te de type 2, a programm茅 deux 茅v茅nements importants pour les investisseurs. La soci茅t茅 publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 et fournira des mises 脿 jour commerciales le 12 ao没t 2025 脿 16h30 ET.
De plus, le PDG Harith Rajagopalan pr茅sentera lors de la 45e conf茅rence annuelle sur la croissance de Canaccord Genuity le 13 ao没t 2025 脿 11h30 ET. Les deux 茅v茅nements seront accessibles en webcast via le site web des relations investisseurs de la soci茅t茅.
Fractyl Health (NASDAQ:GUTS), ein Unternehmen f眉r metabolische Therapien, das sich auf Behandlungen von Fettleibigkeit und Typ-2-Diabetes spezialisiert hat, hat zwei wichtige Investorenveranstaltungen geplant. Das Unternehmen wird seine Finanzergebnisse f眉r das zweite Quartal 2025 ver枚ffentlichen und am 12. August 2025 um 16:30 Uhr ET Gesch盲ftsaktualisierungen geben.
Dar眉ber hinaus wird CEO Harith Rajagopalan auf der 45. j盲hrlichen Wachstumskonferenz von Canaccord Genuity am 13. August 2025 um 11:30 Uhr ET pr盲sentieren. Beide Veranstaltungen sind per Webcast 眉ber die Investor-Relations-Website des Unternehmens zug盲nglich.
- None.
- None.
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the 鈥淐ompany鈥� or 鈥淔ractyl鈥�), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET.
The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET.
A live webcast of the conference call and presentation can be accessed in the 鈥淓vents鈥� section of Fractyl Health鈥檚 website at . The webcast will be archived and available for replay following the live event.
About Fractyl Health听听听听听听听听
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl鈥檚 goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 32 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit鈥�.
颁辞苍迟补肠迟蝉鈥�
Media Contact鈥�
Jessica Cotrone, Head of Corporate Communications
, 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
, 951.206.1200
FAQ
When will Fractyl Health (GUTS) report Q2 2025 earnings?
Where can I watch Fractyl Health's Q2 2025 earnings call?
When is Fractyl Health presenting at the Canaccord Genuity Conference?
What is Fractyl Health's main business focus?
